Sector: MedicalYM BioSciences, Inc. (AMEX: YMI)
Headlines
- YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
Nov 02, 2009 02:09 PM | YMI
- YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Oct 29, 2009 05:30 PM | YMI
- YM BIOSCIENCES INC. - YM BioSciences announces offer
Oct 06, 2009 02:02 AM | YMI
- Cytopia Merger with Toronto-based YM BioSciences Inc.
Oct 05, 2009 09:30 PM | YMI
- YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
Oct 05, 2009 06:31 PM | YMI
- Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities
Sep 29, 2009 03:36 PM | ACCP, ALTH, BBI, BIIB, CTIC, MEDX
- BioMed News Bytes: NicOx, Allos, YM BioSciences
Sep 25, 2009 03:39 PM | ALTH, YMI
- YM BIOSCIENCES REPORTS FISCAL YEAR END 2009 OPERATIONAL AND FINANCIAL RESULTS
Sep 25, 2009 07:05 AM | YMI
- YM BIOSCIENCES INC. - Annual Financial Report
Sep 25, 2009 07:04 AM | YMI
- YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Sep 17, 2009 07:01 AM | YMI
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
YMI
|
Compare to S&P
|
| YTD |
248.84 %
|
204.08 %
|
| 4 Weeks |
-11.64 %
|
-12.58 %
|
| 12 Weeks |
122.38 %
|
116.86 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: -13.44 %
|
|
Sales Growth in Last Quarter: -63.23 %
|
|
